The glaucoma treatment company rebrands to align more closely with goals and direction of the company.
In a strategic move by the company to align their name with their future, BELKIN Laser will now be known as BELKIN Vision. The Israel-based medical device company will continue to supply fast, accessible glaucoma laser treatment as well as reinforcing their focus on additional ophthalmic challenges.
BELKIN Vision made a splash in the glaucoma treatment industry with their fast, no-contact laser. While other glaucoma treatments—such as daily drops or invasive lasers—pose issues of poor patient adherence and significant time requirements, the BELKIN Vision DSLT (Direct SLT) enhances intraocular fluid drainage in about a second via delivery of a single laser beam to the limbus.
"When we started the company in 2013, we always imagined that it would transport us to the stage we're at today. Now, on the cusp of commercialization, we anticipate a multitude of exciting future applications and wanted to ensure that our company name aligned with that vision. We're confident that BELKIN Vision perfectly reflects our future plans and will capture the hearts and minds of our future customers," said Daria Lemann Blumenthal, CEO of BELKIN Vision.
For more information, visit BELKIN Vision’s website.